替诺福韦酯单药治疗慢性乙型肝炎的临床效果

Clinical Efficacy of Tenofovir Disoproxil Alone in the Treatment of Chronic Hepatitis B

目的:探讨替诺福韦酯单药治疗慢性乙型肝炎的临床效果。方法:密集抽样法选取2015年3月-2018年3月笔者所在医院收治的64例慢性乙型肝炎患者。按照随机数字表法将其分为两组,各32例。对照组给予恩替卡韦单药治疗,研究组给予替诺福韦酯单药治疗。比较两组临床疗效。结果:治疗6、12个月时,研究组HBV DNA转阴率分别为68.75%、93.75%,均高于对照组的40.63%、56.25%,差异有统计学意义(χ^2=5.107、12.000,P=0.023、0.000)。治疗6、12个月时,研究组ALT复常率分别为71.88%、96.88%,均高于对照组的43.75%、62.50%,差异有统计学意义(χ^2=5.189、11.680,P=0.022、0.000)。研究组不良反应发生率为6.25%,低于对照组的28.13%,差异有统计学意义(χ^2=5.379,P=0.020)。结论:慢性乙型肝炎采用替诺福韦酯单药治疗效果显著,可提升HBV DNA转阴率、ALT复常率,改善肾功能,且不良反应少,值得临床推广。

Objective:To investigate the clinical efficacy of Tenofovir Disoproxil alone in the treatment of chronic hepatitis B.Method:A total of 64 patients with chronic hepatitis B admitted in our hospital from March 2015 to March 2018 were selected by intensive sampling method.According to the random number table method,they were divided into two groups,with 32 cases in each group.The control group was treated with Entecavir monotherapy,while the study group was treated with Tenofovir Disoproxil monotherapy.The efficacy of the two groups was compared.Result:At 6 and 12 months of treatment,the HBV DNA negative conversion rates in the study group were 68.75%and 93.75%,respectively,which were higher than 40.63%and 56.25%in the control group,the differences were statistically significant(χ^2=5.107,12.000,P=0.023,0.000).At 6 and 12 months of treatment,the ALT recurrence rates in the study group were 71.88%and 96.88%,respectively,which were higher than 43.75%and 62.50%in the control group,the differences were statistically significant(χ^2=5.189,11.680,P=0.022,0.000).The incidence of adverse reactions in the study group was 6.25%,which was lower than 28.13%in the control group,the difference was statistically significant(χ^2=5.379,P=0.020).Conclusion:Tenofovir Disoproxil monotherapy for chronic hepatitis B has a significant therapeutic effect,which can improve the rate of HBV DNA negative conversion and ALT recurrence,improve renal function,and have fewer adverse reactions,which is worthy of clinical promotion.